• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Kiromic BioPharma, Inc. - Common Stock (NQ:KRBP)

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Sep 13, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Kiromic BioPharma, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Kiromic BioPharma Reports Favorable Results at Six Weeks from Fourth Patient in Deltacel-01 Clinical Trial
May 29, 2024
From Kiromic BioPharma, Inc.
Via Business Wire
Kiromic BioPharma Adds UPMC as Fourth Deltacel-01 Clinical Trial Site
May 20, 2024
From Kiromic BioPharma, Inc.
Via Business Wire
KRBP Stock Earnings: Kiromic BioPharma Reported Results for Q1 2024
May 13, 2024
Kiromic BioPharma just reported results for the first quarter of 2024. 
Via InvestorPlace
Kiromic BioPharma Reports Consistent Favorable Safety, Tolerability, and Efficacy in Deltacel-01 Clinical Trial First Three Patients
April 24, 2024
From Kiromic BioPharma, Inc.
Via Business Wire
Kiromic BioPharma Reports Favorable Safety, Tolerability, and Early Efficacy from Third Patient in Deltacel-01 Clinical Trial
April 02, 2024
From Kiromic BioPharma, Inc.
Via Business Wire
Early Efficacy Results Show Primary Lung Tumor Stabilization and Complete Disappearance of Brain Metastases in Second Patient in Kiromic BioPharma’s Deltacel-01 Clinical Trial
March 19, 2024
From Kiromic BioPharma, Inc.
Via Business Wire
Life Science Virtual Investor Forum Presentations Now Available for Online Viewing
March 08, 2024
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
Life Science Virtual Investor Forum Agenda Announced for March 7th, 2024
March 05, 2024
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
Kiromic BioPharma Adds Virginia Oncology Associates, PC as the Second Clinical Trial Site in the Ongoing Phase 1 Deltacel-01 Trial
March 01, 2024
From Kiromic BioPharma, Inc.
Via Business Wire
Kiromic BioPharma to Present at the OTC Markets’ Virtual Life Science Investor Forum on March 7th
February 28, 2024
From Kiromic BioPharma, Inc.
Via Business Wire
Kiromic BioPharma to Present at the OTC Markets’ Virtual Life Science Investor Forum on March 7th
February 28, 2024
Live and Archived Fireside Chat Available at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
Results from First Patient in Kiromic BioPharma’s Deltacel-01 Clinical Trial Indicate Tumor Reduction at Two Months
February 14, 2024
From Kiromic BioPharma, Inc.
Via Business Wire
Kiromic BioPharma Reports Favorable Early Efficacy Results from First Patient in Deltacel-01 Phase 1 Clinical Trial in Non-Small Cell Lung Cancer
January 29, 2024
From Kiromic BioPharma, Inc.
Via Business Wire
Kiromic BioPharma Reports Favorable Early Safety and Tolerability Data from First Patient Enrolled in the Phase 1 Deltacel-01 Clinical Trial
January 05, 2024
From Kiromic BioPharma, Inc.
Via Business Wire
Kiromic BioPharma Announces First Patient Dosed in Phase 1 Study Evaluating Deltacel™ for the Treatment of Non-Small Cell Lung Cancer
December 14, 2023
From Kiromic BioPharma, Inc.
Via Business Wire
Kiromic BioPharma Announces Uplisting to OTCQB Market
November 16, 2023
From Kiromic BioPharma, Inc.
Via Business Wire
Kiromic BioPharma Announces Deltacel™ Phase 1 Clinical Trial Enters Patient Recruitment Phase at Beverly Hills Cancer Center
November 09, 2023
From Kiromic BioPharma, Inc.
Via Business Wire
Kiromic BioPharma and Beverly Hills Cancer Center Enter Clinical Trial Agreement
October 23, 2023
From Kiromic BioPharma, Inc.
Via Business Wire
12 Health Care Stocks Moving In Wednesday's After-Market Session
September 13, 2023
 
Via Benzinga
Kiromic BioPharma Common Stock to Begin Trading on the OTC Pink Sheets on September 14
September 13, 2023
From Kiromic BioPharma
Via Business Wire
Stocks That Hit 52-Week Lows On Tuesday
August 01, 2023
  On Tuesday, 46 stocks hit new 52-week lows. 
Via Benzinga
Kiromic BioPharma Welcomes Two New Directors to its Board
July 24, 2023
From Kiromic BioPharma, Inc.
Via Business Wire
Stocks That Hit 52-Week Lows On Friday
July 28, 2023
  Friday's session saw 59 companies set new 52-week lows. 
Via Benzinga
Why Cineverse Shares Are Trading Lower By 18%? Here Are Other Stocks Moving In Friday's Mid-Day Session
June 30, 2023
Gainers Addentax Group Corp. (NASDAQ: ATXG) shares jumped 47.3% to $9.68. Addentax Group is launching automation of artificial intelligence internet operational tools project with top... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
June 30, 2023
 
Via Benzinga
Why Renalytix Are Trading Higher By Over 48%; Here Are 20 Stocks Moving Premarket
June 30, 2023
Gainers Renalytix Plc (NASDAQ: RNLX) shares surged 48.7% to $3.02 in pre-market trading after the company received FDA De Novo marketing authorization for its KidneyIntelX.dkd prognostic test. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
June 30, 2023
It's the final day of trading this week and we're starting off with a breakdown of the biggest pre-market stock movers worth watching today! 
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's After-Market Session
June 01, 2023
 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
May 10, 2023
 
Via Benzinga
What's Going On With Kiromic BioPharma Stock Wednesday
May 03, 2023
Kiromic BioPharma Inc (NASDAQ: KRBP) shares are gaining Wednesday morning. However, there is no specific news today. During the session, the share price reached $9.22. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
FinancialContent
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap